Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in CD20+ Standard Risk Adult ALL (GMALL 07/2003)
NCT00199004Phase 4Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Apr 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in acute lymphoblastic leukemia (ALL), sponsored by Universitätsklinikum Frankfurt. Primary endpoints: Cytologic Remission Rate, Molecular Remission Rate and 3 more. Started Apr 2004; status: completed.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00199004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199004.